Snehal Patel Purchases 8,000 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Rating) CEO Snehal Patel bought 8,000 shares of the firm’s stock in a transaction on Thursday, June 16th. The stock was acquired at an average price of $7.13 per share, for a total transaction of $57,040.00. Following the transaction, the chief executive officer now owns 2,683,886 shares of the company’s stock, valued at $19,136,107.18. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Snehal Patel also recently made the following trade(s):

• On Tuesday, June 14th, Snehal Patel acquired 12,000 shares of Greenwich LifeSciences stock. The stock was bought at an average cost of $7.91 per share, for a total transaction of $94,920.00.
• On Thursday, June 9th, Snehal Patel bought 4,500 shares of Greenwich LifeSciences stock. The shares were purchased at an average cost of $10.90 per share, for a total transaction of $49,050.00.
• On Tuesday, June 7th, Snehal Patel acquired 6,000 shares of Greenwich LifeSciences stock. The stock was acquired at an average price of $8.55 per share, with a total value of $51,300.00.
• On Thursday, June 2nd, Snehal Patel purchased 6,774 shares of Greenwich LifeSciences stock. The stock was acquired at an average cost of $7.38 per share, for a total transaction of $49,992.12.
• On Thursday, April 21st, Snehal Patel purchased 6,000 shares of Greenwich LifeSciences stock. The shares were bought at an average price of $16.09 per share, for a total transaction of $96,540.00.
• On Tuesday, April 19th, Snehal Patel acquired 6,000 shares of Greenwich LifeSciences stock. The shares were bought at an average price of $16.74 per share, with a total value of $100,440.00.

Shares of GLSI opened at $7.14 on Friday. The business has a fifty day moving average of $11.27 and a 200 day moving average of $18.47. Greenwich LifeSciences, Inc. has a one year low of $6.82 and a one year high of $48.96.

Several large investors have recently bought and sold shares of GLSI. Bank of America Corp DE grew its stake in shares of Greenwich LifeSciences by 106.4% during the second quarter. Bank of America Corp DE now owns 770 shares of the company’s stock valued at $35,000 after buying an additional 397 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Greenwich LifeSciences by 1,776.8% during the 4th quarter. Wells Fargo & Company MN now owns 2,346 shares of the company’s stock valued at $57,000 after purchasing an additional 2,221 shares during the last quarter. Royal Bank of Canada raised its stake in Greenwich LifeSciences by 9.9% in the 2nd quarter. Royal Bank of Canada now owns 3,076 shares of the company’s stock worth $138,000 after acquiring an additional 276 shares during the last quarter. UBS Group AG raised its stake in Greenwich LifeSciences by 467.1% in the 3rd quarter. UBS Group AG now owns 4,310 shares of the company’s stock worth $168,000 after acquiring an additional 3,550 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new position in Greenwich LifeSciences in the 4th quarter worth $107,000. Institutional investors own 6.15% of the company’s stock.

About Greenwich LifeSciences (Get Rating)

Greenwich LifeSciences, Inc, a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.

Further Reading

• Get a free copy of the StockNews.com research report on Greenwich LifeSciences (GLSI)
• Vuzix Stock Stays Optimistic
• Palo Alto Networks: Pioneering AI in Cybersecurity
• The Analysts Upgrade… Retail Stocks? 
• Dividend Stocks and Your Roth IRA
• The Q2 Earnings Season Could Be A Bloodbath 

Want More Great Investing Ideas?